CTOR (Citius Oncology) Other Financing : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Other Financing?

Citius Oncology's Other Financing for the six months ended in Sep. 2023 was $0.00 Mil.

Citius Oncology's Other Financing for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Citius Oncology Other Financing Historical Data

The historical data trend for Citius Oncology's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Other Financing Chart

Citius Oncology Annual Data

Trend

Sep22

Other Financing

Citius Oncology Semi-Annual Data
	Sep22	Sep23
Other Financing	-	-

Citius Oncology Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Other Financing for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Citius Oncology Other Financing Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Other Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Ave, Suite 2446, New York, NY, USA, 10170

Website

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.